Also, the combination of one silymarin component—quercetin with doxorubicin—significantly increased the doxorubicin sensitivity of doxorubicin-resistant breast cancer (MCF-7) cells and quercetin also decreased P-gp expression [49]. The gene discussed is PGP; the disease is breast carcinoma.